Skip to main content

Table 3 Clinical PET studies using [18F]AlF-NOTA-octreotide

From: The aluminium-[18F]fluoride revolution: simple radiochemistry with a big impact for radiolabelled biomolecules

Year Study No
Participants
Outcome References
[18F]AlF-NOTA-octreotide
 2019 First comparison with [68Ga]Ga-DOTATATE in diffuse metastases of rectal NET 1 [18F]AlF-NOTA-octreotide was a promising clinical alternative for [68Ga]Ga-DOTATATE and warrants further head-to-head evaluation Pauwels et al. (2019)
 2019 Biodistribution, safety and dosimetry in healthy volunteers. Detection of neuroendocrine neoplasms (NENs) in patients Healthy: 3
Patients: 22
[18F]AlF-NOTA-octreotide was well tolerated and provided superior imaging of well-differentiated NENs. Tumour-to-background ratios were significantly higher compared to [18F]FDG Long et al. (2019)
 2020 Biodistribution, dosimetry and comparison with [68Ga]Ga-DOTATATE in NETs Healthy: 6
Patients: 6
[18F]AlF-NOTA-octreotide was safe and well tolerated. Lesion detection rate and tumour-to-background ratios were comparable to [68Ga]Ga-DOTATATE Pauwels et al. (2020)
 2020 Head-to-head comparison with [68Ga]Ga-DOTATATE in patients with NENs Healthy: 3
Patients: 8
[18F]AlF-NOTA-octreotide produces similar image quality and fine detection rate of lesions, especially in the liver, because of lower liver background uptake than [68Ga]Ga-DOTATATE Hou et al. (2020)